Life science & clinical diagnostics instruments

Genes, male beauty and attractiveness to the other gender

19 August, 2013

It’s a simple fact: some individuals are more attractive to the opposite sex than others. But what makes them more desirable?


Greiner Bio-One CELLrepellant Surface range

13 August, 2013 | Supplied by: Interpath Services Pty Ltd

The Greiner Bio-One CELLrepellant Surface range is now available from Interpath Services. The surface technology effectively inhibits cell attachment.


Glue ear mystery comes unstuck

12 August, 2013

Research from the University of Western Australia (UWA) could have a significant impact on the treatment of ear infections, reducing the need for antibiotics and surgery and tackling hearing loss in Indigenous communities.


Over 10,000 proteins in cancer cells identified

09 August, 2013

Researchers at Technische Universität München (TUM) have decoded the proteome of 59 tumour cell lines from the US National Cancer Institute, known as the ‘NCI-60’ cell lines, which represent the most common tumour diseases in nine tissues (eg, brain, breast, bowels, skin, blood).


GE Healthcare Biacore 4000 molecular interaction analysis system

07 August, 2013 | Supplied by: Global Life Sciences Solutions

The Biacore 4000 offers a complete solution for large-scale, label-free molecular interaction analysis, delivering high throughput without compromising on data quality.


GE Healthcare MicroCal iTC200 biomolecular interaction measurement system

07 August, 2013 | Supplied by: Global Life Sciences Solutions

The MicroCal iTC200 allows direct and label-free measurement of binding affinity and thermodynamic parameters from biomolecular interactions. All binding parameters (affinity, stoichiometry, enthalpy and entropy) are available in a single experiment.


GE Healthcare Biacore T200 biomolecular interaction analysis system

06 August, 2013 | Supplied by: Global Life Sciences Solutions

The Biacore T200 is a versatile, label-free system for detailed studies of biomolecular interactions, from early research to drug discovery and development and on to QC.


Why one person’s mutation kills when the same mutation in someone else is benign

02 August, 2013

Scientists have begun to understand how the rest of the genome interacts with mutations, explaining why not everyone with identical genetic mutations develops a disease.


Bacteria invest in evolutionary success

02 August, 2013

Researchers at Sydney and Exeter Universities have, for the first time, recreated and analysed the complex interplay between bacterial investment strategies and their outcomes.


GeneCopoeia Genome-TALER Human AAVS1 Safe Harbor Knock-in ORF Clones

31 July, 2013 | Supplied by: United Bioresearch Products Pty Ltd

Genome-TALER Human AAVS1 Safe Harbor Knock-in ORF Clones from GeneCopoeia are constructed for specifically transferring the ORF of interest from a donor plasmid into the AAVS1 safe harbour site in human chromosome 19 using the Genome-TALER Human AAVS1 Safe Harbor Gene Knock-in Kit.


Evolution is a group effort

29 July, 2013

Researchers have found that rather than just one mutation causing enhanced survival, about five to seven mutations are required. These extra mutations are termed ‘genetic hitchhikers’ because they don’t appear to contribute to the enhanced fitness of the organism.


FDA permits marketing of TB bacteria and antibiotic-resistance test

26 July, 2013

The US Food and Drug Administration (FDA) has authorised the marketing of the Xpert MTB/RIF assay, manufactured by Cepheid. This is the first FDA-reviewed test that can rapidly detect the bacteria that cause tuberculosis (TB) and determine if the bacteria contain genetic markers that make them resistant to rifampin, an important antibiotic for the treatment of TB.


Qiagen and Exosome Diagnostics partner to create biofluid sample preparation kits

24 July, 2013

Qiagen and Exosome Diagnostics have announced a partnership to develop and commercialise high-performance kits for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles.


Now they tell us - high omega-3 fatty acids levels increase risk of prostate cancer

19 July, 2013

Fatty acids derived from fatty fish and fish-oil supplements, usually lauded as ‘cure-alls’, have been found to increase the risk of developing aggressive prostate cancer.


Biobase ELISA microplate reader

17 July, 2013 | Supplied by: Crea Laboratory Technologies Pty Ltd

Biobase has produced the ELISA microplate reader, suitable for a wide range of uses in the fields of hospital clinical diagnosis, immune pathology testing, microbial antigen and antibody detection, parasitic diseases diagnosis, blood diseases diagnosis, endocrine disorder measure, plant diseases and insect pet studies.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd